ADDING MULTIMEDIA Launch of Organon as a new global women’s health company


Content of the article

The only company of its size focused on women’s health

Launch with a commitment to listen to women to understand their health needs and help identify solutions that are urgently needed

JERSEY CITY, NJ – Organon (NYSE: OGN), today celebrates its launch as a global women’s health company with employees and women around the world, as Organon’s leadership team rings the bell the opening bell on the New York Stock Exchange (NYSE). Recognizing the need to listen to and act on women’s experiences to address women’s health challenges, Organon brought together voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE.

Organon is committed to meeting the daily health needs of women, with a focus on reproductive health, health issues unique to women, as well as conditions that disproportionately affect women. The “Wall of Voices” shares powerful perspectives, voices and images of women around the world highlighting these health issues and serves as a symbol of Organon’s commitment. Women everywhere are invited to take the “microphone” to add their voice to the digital “Wall of Voices” at HerePourSaSanté.com.


Content of the article

“At Organon, we are there for his health. Our vision is to create a better and healthier daily life for every woman around the world. There is no other healthcare company with our global footprint dedicated to putting women at the center that will focus on identifying the drugs and solutions they so urgently need, ”said Kevin Ali, CEO from Organon. “Now is the time for Organon to bring more options to women and healthcare providers to help shape the future of women’s health.

A diversified portfolio will foster sustainable growth

At launch, Organon’s portfolio will consist of more than 60 drugs and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately $ 6.5 billion in annual revenue generated. outside the United States. Organon believes it is well positioned for low to mid single-digit organic growth relative to its 2021 business base.

Organon is built on three main pillars that will benefit from renewed leadership direction and business investments:

  • Women’s health: Anchored by NEXPLANON (etonogestrel implant), a long-acting reversible contraception, as well as its contraception and fertility businesses and strengthened by its recently announced plan to acquire Alydia Health, a medical device company focused on the prevention of maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.
  • Biosimilars: A key pillar of growth with products available in various parts of the world including RENFLEXIS (infliximab-abda) and BRENZYS (etanercept) in immunology and ONTRUZANT (trastuzumab-dttb) in oncology. Organon’s expertise lies in bringing these products to market, bringing them to more people around the world.
  • Established brands: 49 products recognized in the fields of respiratory, cardiovascular, dermatological and non-opioid pain.

Women at the center: Organon’s approach to innovation

Organon’s R&D philosophy is to build a business around the needs of patients, with the goal of identifying and advancing healthcare options for women that enable them to live their best lives every day.

“For too long, for too many common conditions, such as heavy, painful and irregular menstrual bleeding, incontinence and menopause and many more, women have been told to accept and normalize these conditions as part of of life, ”said Sandy Milligan, Organon’s head of research and development. “Organon’s mission is to change that. We believe this approach will be very successful – we hope to discover the ability to identify diseases earlier, the ability to alter the course of diseases or health conditions, and ultimately improve quality of life. women at all stages.


Content of the article

The company’s broad global capabilities in clinical development and patient safety, regulatory and medical affairs make it well positioned to identify promising drugs, diagnostics and devices with the greatest potential for health impact. women.

The predominantly female board of directors will guide the team of committed employees

Organon believes the journey to improve women’s health is fundamental to the gender equity he wants to see in his organization. The representation of women on the board – comprising 70% of positions – is higher than any healthcare company in the S&P 500. Along with Organon employees, a global community of approximately 9,000 people, they are united in their desire to better support women’s health around the world.

A live webcast of the stock market opening bell will be available on the The NYSE site today starting at 9:30 a.m. EST.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed by a spin-off of Merck, known as MSD outside of the United States and Canada, to focus on improving women’s health. throughout their life. Here for its health, the company has a portfolio of more than 60 drugs and products in a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and a stable established drug franchise, Organon’s products generate strong cash flow that will support investments in future growth opportunities in the field of women’s health, including business development. Additionally, Organon is seeking collaboration opportunities with biopharmaceutical innovators who seek to commercialize their products by leveraging its scale and presence in rapidly growing international markets.

Organon has a global presence with significant scale and geographic reach, world-class business capabilities and approximately 9,000 employees headquartered in Jersey City, New Jersey.

For more information visit and connect with us on LinkedIn and Instagram.

Forward-looking statement from Organon & Co., Jersey City, NJ, United States

This press release from Organon & Co. (the “Company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified. by words such as “expects”, “intends to”, “anticipates”, “plans”, “believes”, “research”, “estimates”, “want” or words with similar meaning. These statements are based on the current beliefs and expectations of the management of the company and are subject to significant risks and uncertainties. If the underlying assumptions prove to be incorrect or if risks or uncertainties materialize, actual results may differ materially from those stated in forward-looking statements.


Content of the article

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including fluctuations in interest rates and exchange rates; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and globally; global trends towards containing health care costs; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of patents and other corporate protections for innovative products; and exposure to litigation, including patent litigation, and / or regulatory actions.

The company does not undertake to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in forward-looking statements can be found in the documents filed by the company with the Securities and Exchange Commission (SEC), including its registration statement on the Form 10, available on the SEC website (

View the source version on




Karissa peer
(614) 314-8094

Kate vossen
(732) 675-8448


Jennifer halchak
(201) 275-2711

Edouard Barger
(267) 614-4669



In-depth reporting on The Logic’s innovation economy, presented in partnership with the Financial Post.


Postmedia is committed to maintaining a lively but civil discussion forum and encourages all readers to share their views on our articles. Comments may take up to an hour of moderation before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread that you follow, or if a user that you follow comments. Visit our Community rules for more information and details on how to adjust your E-mail The settings.


About Author

Comments are closed.